Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study
We detected rare emergent InSTI RAMs and few emergent NRTI RAMs in PLWH failing DTG- or BIC-based regimens in FL or SL. The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV.
Authors
- François Durand (ORCID: https://orcid.org/0000-0002-0357-1090)
- Vincent Cálvez (ORCID: https://orcid.org/0009-0002-6855-3472)
- Anne‐Geneviève Marcelin (ORCID: https://orcid.org/0000-0003-4808-8999)
- Diane Descamps (ORCID: https://orcid.org/0000-0002-6556-1525)
- Marc Wirden (ORCID: https://orcid.org/0009-0003-3723-4142)
- Charlotte Charpentier
- Guillaume Barriere (ORCID: https://orcid.org/0009-0006-4776-4827)
- Cathia Soulié (ORCID: https://orcid.org/0009-0008-2032-4148)
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Gilead Sciences (France) (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1093/jac/dkae377
- Citations
- 10
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.50
Funders
- Gilead Sciences